GA
ESPR

Greenspring Associates’s Esperion Therapeutics ESPR Stock Holding History

Greenspring Associates’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,633
Closed -$628K – 10
2019
Q1 		$628K Buy
+15,633
New +$701K 0.24% 5

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Greenspring Associates's ESPR Position: Q2 2019 in Review

Greenspring Associates sold out of Esperion Therapeutics (ESPR) in Q2 2019, closing a stake of 15,633 shares — an estimated $628K sold.

Greenspring Associates first reported a position in ESPR in Q1 2019 and held it in 1 quarter. The position peaked at $628K in Q1 2019. 167 funds tracked by Wall St. Rank hold ESPR as of Q2 2019.

  • Greenspring Associates reported no remaining Esperion Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Greenspring Associates sold 15,633 Esperion Therapeutics shares in Q2 2019, an estimated $628K.
  • Greenspring Associates first reported a position in Esperion Therapeutics in Q1 2019 and held it in 1 quarter.
  • Greenspring Associates's Esperion Therapeutics position peaked at $628K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2019.

Based on Greenspring Associates's 13F filing for Q2 2019, filed 14 Feb 2020.